JP7084946B2 - 置換窒素含有化合物 - Google Patents

置換窒素含有化合物 Download PDF

Info

Publication number
JP7084946B2
JP7084946B2 JP2019566121A JP2019566121A JP7084946B2 JP 7084946 B2 JP7084946 B2 JP 7084946B2 JP 2019566121 A JP2019566121 A JP 2019566121A JP 2019566121 A JP2019566121 A JP 2019566121A JP 7084946 B2 JP7084946 B2 JP 7084946B2
Authority
JP
Japan
Prior art keywords
methyl
oxo
dihydroisobenzofuran
piperazine
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019566121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522490A (ja
JP2020522490A5 (enExample
Inventor
ナブナト・ドニャノバ・ヤダブ
ラジーブ・エス・ビデ
ラジェシュ・オンカルダス・ボラ
プラシャンタ・グナガ
マノランジャン・パンダ
エルドン・スコット・プリーストリー
ジェレミー・リヒター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020522490A publication Critical patent/JP2020522490A/ja
Publication of JP2020522490A5 publication Critical patent/JP2020522490A5/ja
Priority to JP2022090971A priority Critical patent/JP7406592B2/ja
Application granted granted Critical
Publication of JP7084946B2 publication Critical patent/JP7084946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
JP2019566121A 2017-06-01 2018-05-31 置換窒素含有化合物 Active JP7084946B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022090971A JP7406592B2 (ja) 2017-06-01 2022-06-03 置換窒素含有化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201711019293 2017-06-01
IN201711019293 2017-06-01
IN201811004486 2018-02-06
IN201811004486 2018-02-06
PCT/US2018/035270 WO2018222795A1 (en) 2017-06-01 2018-05-31 Substituted nitrogen containing compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022090971A Division JP7406592B2 (ja) 2017-06-01 2022-06-03 置換窒素含有化合物

Publications (3)

Publication Number Publication Date
JP2020522490A JP2020522490A (ja) 2020-07-30
JP2020522490A5 JP2020522490A5 (enExample) 2021-06-10
JP7084946B2 true JP7084946B2 (ja) 2022-06-15

Family

ID=62685190

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566121A Active JP7084946B2 (ja) 2017-06-01 2018-05-31 置換窒素含有化合物
JP2022090971A Active JP7406592B2 (ja) 2017-06-01 2022-06-03 置換窒素含有化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022090971A Active JP7406592B2 (ja) 2017-06-01 2022-06-03 置換窒素含有化合物

Country Status (27)

Country Link
US (6) US10501449B2 (enExample)
EP (2) EP3630752B1 (enExample)
JP (2) JP7084946B2 (enExample)
KR (1) KR102655318B1 (enExample)
CN (1) CN110678463B (enExample)
AU (1) AU2018275552B2 (enExample)
CA (1) CA3065309A1 (enExample)
CL (1) CL2019003486A1 (enExample)
CO (1) CO2019013589A2 (enExample)
CY (1) CY1124479T1 (enExample)
DK (1) DK3630752T3 (enExample)
ES (2) ES2885243T3 (enExample)
HR (1) HRP20211262T1 (enExample)
HU (1) HUE056142T2 (enExample)
IL (1) IL271036B2 (enExample)
LT (1) LT3630752T (enExample)
MX (1) MX389581B (enExample)
MY (1) MY201325A (enExample)
PE (1) PE20200386A1 (enExample)
PL (1) PL3630752T3 (enExample)
PT (1) PT3630752T (enExample)
RS (1) RS62277B1 (enExample)
SI (1) SI3630752T1 (enExample)
SM (1) SMT202100512T1 (enExample)
TW (1) TWI791527B (enExample)
WO (1) WO2018222795A1 (enExample)
ZA (1) ZA201908488B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022130404A (ja) * 2017-06-01 2022-09-06 ブリストル－マイヤーズ スクイブ カンパニー 置換窒素含有化合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201903871TA (en) 2016-11-03 2019-05-30 Bristol Myers Squibb Co Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
CN114980887A (zh) 2019-12-20 2022-08-30 特纳亚治疗股份有限公司 氟代烷基-噁二唑及其用途
EP4146219A4 (en) * 2020-05-06 2024-05-22 Biohaven Therapeutics Ltd. PROCESS FOR PREPARING VERDIPERSTAT
WO2022235842A1 (en) 2021-05-04 2022-11-10 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
CN114957222B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 化合物及其制备方法和用途
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用
WO2025264844A1 (en) * 2024-06-20 2025-12-26 Lieber Institute, Inc. Heterocyclic gpr52 modulators and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039802A1 (en) 2011-09-16 2013-03-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013090271A1 (en) 2011-12-16 2013-06-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014099633A2 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP2014521751A (ja) 2011-08-19 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 腎髄質外層カリウムチャンネルの阻害薬
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1106605A4 (en) 1999-06-24 2005-12-07 Toray Industries ANTAGONISTS OF THE ADRENERGIC RECEPTOR-ALPHA1B
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CN100376592C (zh) 2001-06-20 2008-03-26 橘生药品工业株式会社 含氮的杂环衍生物、含有该衍生物的药物组合物、其药物应用以及用于该衍生物制备的中间体
WO2003086279A2 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
AU2005263719A1 (en) 2004-07-16 2006-01-26 Janssen Pharmaceutica N.V. Dimeric piperidine derivatives
CA2588517A1 (en) 2004-12-01 2006-06-08 Devgen N.V. 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
BRPI0908565A2 (pt) 2008-03-06 2017-05-23 Anacor Pharmaceuticals Inc composto, formulação farmacêutica, métodos para reduzir a liberação de uma citocina ou de uma quimiocina, para tratar uma condição em um animal e para inibir uma fosfodiesterase
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP5654572B2 (ja) 2009-05-15 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011103536A1 (en) 2010-02-19 2011-08-25 Arizona Board Of Regents Multifunctional radical quenchers and their use
AU2011302216A1 (en) 2010-09-14 2013-04-04 Exelixis, Inc. Phtalazine derivatives as JAK1 inhibitors
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999991B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062892A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773351B1 (en) 2011-10-31 2017-08-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066717A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014015495A1 (en) 2012-07-26 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
WO2014085210A1 (en) 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections
US9604998B2 (en) 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2968288B1 (en) 2013-03-15 2018-07-04 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015017305A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
HUE041652T2 (hu) 2013-10-11 2019-05-28 Hoffmann La Roche TRPA1-modulátorokként hasznos szubsztituált heterociklusos szulfonamid-vegyületek
EP3083573B1 (en) 2013-12-18 2024-08-07 Merck Sharp & Dohme LLC Inhibitors of the renal outer medullary potassium channel
WO2015090579A1 (en) 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
WO2015096035A1 (en) 2013-12-24 2015-07-02 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2015103756A1 (en) 2014-01-09 2015-07-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016008064A1 (en) 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
MX2017000634A (es) 2014-07-14 2017-05-01 Merck Sharp & Dohme Inhibidores del canal de potasio medularmente externo renal.
WO2016060941A1 (en) 2014-10-14 2016-04-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065582A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065603A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US20170275292A1 (en) 2014-10-31 2017-09-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065602A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2016091042A1 (zh) 2014-12-08 2016-06-16 江苏恒瑞医药股份有限公司 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用
CN105693706B (zh) 2014-12-10 2019-11-22 江苏恒瑞医药股份有限公司 异苯并呋喃酮类衍生物、其制备方法及其在医药上的应用
US10513518B2 (en) 2015-01-29 2019-12-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2017001991A1 (en) 2015-06-29 2017-01-05 Crystalmorphix Technologies Pvt. Ltd Cocrystals of trigonelline
EA037300B1 (ru) 2016-04-20 2021-03-05 Бристол-Маерс Сквибб Компани Замещенные бициклические гетероциклические соединения
SG11201903871TA (en) 2016-11-03 2019-05-30 Bristol Myers Squibb Co Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
CN110678463B (zh) 2017-06-01 2023-06-06 百时美施贵宝公司 经取代的含氮化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521751A (ja) 2011-08-19 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 腎髄質外層カリウムチャンネルの阻害薬
WO2013039802A1 (en) 2011-09-16 2013-03-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013090271A1 (en) 2011-12-16 2013-06-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014099633A2 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARETZ, Christopher D.，Journal of Medicinal Chemistry，2019年，62，8682-8694
DEORAZIO, Russell J.，Synthetic Communications，2011年，41，3551-3555，Entry 6 compound

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022130404A (ja) * 2017-06-01 2022-09-06 ブリストル－マイヤーズ スクイブ カンパニー 置換窒素含有化合物
JP7406592B2 (ja) 2017-06-01 2023-12-27 ブリストル－マイヤーズ スクイブ カンパニー 置換窒素含有化合物

Also Published As

Publication number Publication date
USRE49700E1 (en) 2023-10-17
CN110678463B (zh) 2023-06-06
HUE056142T2 (hu) 2022-01-28
IL271036A (en) 2020-01-30
KR20200011986A (ko) 2020-02-04
TWI791527B (zh) 2023-02-11
WO2018222795A1 (en) 2018-12-06
SI3630752T1 (sl) 2021-10-29
CY1124479T1 (el) 2022-07-22
PE20200386A1 (es) 2020-02-24
MX2019014411A (es) 2020-02-05
SMT202100512T1 (it) 2021-11-12
CN110678463A (zh) 2020-01-10
US10501449B2 (en) 2019-12-10
US20240327390A1 (en) 2024-10-03
RS62277B1 (sr) 2021-09-30
ZA201908488B (en) 2023-10-25
BR112019024950A2 (pt) 2020-06-23
AU2018275552A1 (en) 2020-01-23
EP3929194B1 (en) 2024-04-17
HRP20211262T1 (hr) 2021-11-12
PT3630752T (pt) 2021-08-10
AU2018275552B2 (en) 2022-01-20
IL271036B2 (en) 2023-03-01
EP3630752A1 (en) 2020-04-08
CO2019013589A2 (es) 2020-04-01
ES2981919T3 (es) 2024-10-11
LT3630752T (lt) 2021-08-25
EP3630752B1 (en) 2021-06-30
IL271036B (en) 2022-11-01
US20230124468A1 (en) 2023-04-20
DK3630752T3 (da) 2021-08-09
US20200339550A1 (en) 2020-10-29
MY201325A (en) 2024-02-16
US20180346453A1 (en) 2018-12-06
PL3630752T3 (pl) 2021-11-02
US20200109135A1 (en) 2020-04-09
JP2020522490A (ja) 2020-07-30
JP2022130404A (ja) 2022-09-06
KR102655318B1 (ko) 2024-04-04
EP3929194A1 (en) 2021-12-29
JP7406592B2 (ja) 2023-12-27
TW201902888A (zh) 2019-01-16
CA3065309A1 (en) 2018-12-06
ES2885243T3 (es) 2021-12-13
MX389581B (es) 2025-03-20
CL2019003486A1 (es) 2020-05-15

Similar Documents

Publication Publication Date Title
JP7406592B2 (ja) 置換窒素含有化合物
JP7760530B2 (ja) ピペラジン環状尿素類
KR20250168210A (ko) 헤테로시클릭 glp-1 효능제
JP7102404B2 (ja) 置換窒素含有化合物
HK40064495A (en) Substituted nitrogen containing compounds
BR112019024950B1 (pt) Compostos contendo nitrogênio substituído, composições farmacêuticas e seus usos
EA043056B1 (ru) Замещенные азотсодержащие соединения
HK40024609B (en) Substituted nitrogen containing compounds
HK40024609A (en) Substituted nitrogen containing compounds
HK40087839A (zh) 哌嗪环状脲
TW202508562A (zh) 雜環ｇｌｐ－１促效劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220603

R150 Certificate of patent or registration of utility model

Ref document number: 7084946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250